1. Home
  2. YQ vs ALLR Comparison

YQ vs ALLR Comparison

Compare YQ & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YQ

17 Education & Technology Group Inc.

HOLD

Current Price

$2.29

Market Cap

23.7M

Sector

Real Estate

ML Signal

HOLD

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$1.43

Market Cap

25.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YQ
ALLR
Founded
2012
2004
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.7M
25.6M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
YQ
ALLR
Price
$2.29
$1.43
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.75
AVG Volume (30 Days)
4.7K
227.3K
Earning Date
06-09-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$320,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.70
$0.77
52 Week High
$6.45
$2.35

Technical Indicators

Market Signals
Indicator
YQ
ALLR
Relative Strength Index (RSI) 43.26 45.55
Support Level $1.95 $1.29
Resistance Level $2.62 $1.80
Average True Range (ATR) 0.15 0.14
MACD -0.02 -0.04
Stochastic Oscillator 11.51 31.91

Price Performance

Historical Comparison
YQ
ALLR

About YQ 17 Education & Technology Group Inc.

17 Education & Technology Group Inc is engaged in providing education and education technology services in the People's Republic of China (PRC) with a focus on the Teaching and Learning SaaS offerings. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

Share on Social Networks: